Climb Bio, Inc.

NASDAQ: CLYM · Healthcare · Biotechnology

PublicHQ Wellesley Hills, DECIK 0001768446Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 62DQ —GM —SS 44

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$59.9M

Employees

Market cap

$879.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$59.9M-$59.9M2025

Operating income-$67.9M-$67.9M2025

Total assets$167.7M$167.7M2025

Liabilities$7.3M$7.3M2025

Equity$160.5M$160.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Climb Bio, Inc. earned -$59.9M in FY2025 net income.

Peers · Healthcare

Theravance Biopharma Inc75B+Geron Corporation50D Talkspace, Inc.71B Alto Neuroscience, Inc.——

Key facts

CEOAoife Brennan BCh MMSc

SectorHealthcare

IndustryBiotechnology

HeadquartersWellesley Hills, DE

ExchangeNASDAQ: CLYM

Employees17

IPO date2021-08-10

Latest filings

8-K2026-07-01 8-K2026-06-12 8-K2026-06-11 8-K2026-06-08 8-K2026-06-05 8-K2026-05-07 10-Q2026-05-07 8-K2026-05-05

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.